Syncor International’s 2nd-Quarter Profit Up 35%

Syncor International Corp., a Chatsworth provider of specialty pharmaceutical services, said its fiscal second-quarter profit surged 35% to $2.85 million, from $2.11 million a year earlier.

For the quarter that ended Nov. 30, the company’s revenue rose 8% to $61.2 million, from $56.9 million a year earlier. Syncor attributed the improved results partly to its recent strategic alliance with its principal supplier of radiopharmaceuticals, DuPont Merck Pharmaceutical Co.

For the six months that ended Nov. 30, Syncor posted a profit of $5.71 million, up 31% from $4.35 million a year earlier. Its six-month period sales totaled $121.7 million, up 8% from $112.5 million.